We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...